| Literature DB >> 35222672 |
Jinsong Yang1, Fanjun Yu1, Keyi Lin1, Haotian Qu1, Yihan He2,3, Jing Zhao4, Fen Feng5, Litao Pan6, Yu Kui3.
Abstract
AIM: To assess the reporting quality of randomized controlled trials (RCTs) on acupuncture for primary insomnia (PI).Entities:
Year: 2022 PMID: 35222672 PMCID: PMC8872660 DOI: 10.1155/2022/5157870
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Process and results of literature screening.
Figure 2Information of included papers (n = 102).
Assessment of reporting quality using items from the CONSORT statement (n = 102 studies).
| Criteria | Item | Description | Number of positive trials | % | Cohen's | 95% CI |
|---|---|---|---|---|---|---|
| Title and abstract | 1a | Identification as a randomized trial in the title | 15 | 14.71 | 1.00 | 1.00 |
| 1b | Structured abstract including trial design, methods, results, and conclusions | 102 | 100 | 1.00 | 1.00 | |
| Background and objectives | ||||||
| Introduction | 2a | Scientific background and explanation of rationality | 98 | 96.08 | 0.85 | 0.57 to 1.13 |
| 2b | Specific objectives or hypotheses | 102 | 100 | 1.00 | 1.00 | |
| Trial design | ||||||
| Methods | 3a | Description of trial design | 102 | 100 | 0.66 | 0.04 to 1.28 |
| 3b | Important changes to methods after trial commencement (such as eligibility criteria), with reasons | 0 | 0 | 1.00 | 1.00 | |
| Participants | ||||||
| 4a | Eligibility criteria for participants | 102 | 100 | 1.00 | 1.00 | |
| 4b | Settings and locations where the data were collected | 100 | 98.04 | 0.66 | 0.04 to 1.28 | |
| Interventions | ||||||
| 5 | Interventions for each group with sufficient details to allow replication | 101 | 99.02 | 1.00 | 1.00 | |
| 5a | Procedure for tailoring the interventions to participants | 102 | 100 | 1.00 | 1.00 | |
| 5b | Details of whether and how the interventions were standardized | 12 | 11.76 | 0.77 | 0.59 to 0.95 | |
| 5c | Adherence of researchers to the protocol: whether they adhere to it and how to assess that | 5 | 4.90 | 0.7 | 0.42 to 0.98 | |
| 5d | Adherence of participants to the intervention: whether they adhere to it and how to assess that | 0 | 0 | 1.00 | 1.00 | |
| Outcomes | ||||||
| 6a | Precisely defined prespecified primary and secondary outcome measures | 87 | 85.29 | 0.84 | 0.69 to 0.99 | |
| 6b | Any changes to trial outcomes after trial commencement with reasons | 1 | 0.98 | 1.00 | 1.00 | |
| Sample size | ||||||
| 7a | How sample size was determined | 14 | 13.73 | 0.87 | 0.73 to 1.01 | |
| 7b | Explanation of interim analyses and suspension principles | 17 | 16.67 | 0.73 | 0.57 to 0.89 | |
| Sequence generation | ||||||
| Randomization | 8a | Method used to generate the random allocation sequence | 69 | 67.65 | 0.87 | 0.77 to 0.97 |
| 8b | Type of randomization with details of any restriction | 4 | 3.92 | 0.66 | 0.22 to 1.10 | |
| Allocation concealment mechanism | ||||||
| 9 | Description of the method used to implement the random allocation sequence (such as sequentially numbered containers), assuring concealment until interventions were assigned | 34 | 33.33 | 0.91 | 0.82 to 1.00 | |
| Implementation | ||||||
| 10 | Who generated the random allocation sequence, who enrolled participants, and who assigned intervention to participants | 10 | 9.80 | 0.95 | 0.86 to 1.04 | |
| Blinding | ||||||
| 11a | If done, who was blinded and how | 23 | 22.55 | 0.89 | 0.79 to 0.99 | |
| 11b | If relevant, description of the similarity of interventions | 9 | 8.82 | 0.8 | 0.61 to 0.99 | |
| 11c | If blinding was not possible, description of attempts to limit bias | 7 | 6.86 | 0.82 | 0.58 to 1.06 | |
| Statistical methods | ||||||
| 12a | Statistical methods used to compare groups for primary and secondary outcomes | 100 | 98.04 | 0.69 | 0.43 to 0.95 | |
| 12b | Methods for additional analyses, such as subgroup analyses and adjusted analyses | 2 | 1.96 | 1.00 | 1.00 | |
| Participant flow | ||||||
| Results | 13a | For each group, the numbers of participants randomly assigned, received intended treatment, and analyzed for the outcome indicator | 102 | 100 | 1.00 | 1.00 |
| 13b | For each group, the number of losses and exclusions after randomization with reasons | 33 | 32.35 | 0.91 | 0.84 to 0.98 | |
| 13c | For each group, report of the delay from randomization to the initiation of the intervention | 4 | 3.92 | 0.85 | 0.57 to 1.13 | |
| Recruitment | ||||||
| 14a | Periods of recruitment and follow-up | 55 | 53.92 | 0.85 | 0.75 to 0.95 | |
| 14b | Why the trial suspended | 0 | 00 | 1.00 | 1.00 | |
| Baseline data | ||||||
| 15 | A table showing baseline demographic and clinical characteristics for each group | 62 | 60.78 | 1.00 | 1.00 | |
| Numbers analyzed | ||||||
| 16 | The number of participants in each group included in each analysis and whether they were analyzed according to the original grouping | 102 | 100 | 1.00 | 1.00 | |
| Outcomes and estimation | ||||||
| 17a | The results of primary and secondary outcome indicators, the estimated value of effect size and its accuracy | 5 | 4.90 | 0.88 | 0.65 to 1.11 | |
| 17b | For dichotomous outcomes, recommendation to provide both absolute and relative effect values | 0 | 0 | 1.00 | 1.00 | |
| Ancillary analyses | ||||||
| 18 | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing prespecified analysis from exploratory one | 2 | 1.96 | 1.00 | 1.00 | |
| Harms | ||||||
| 19 | All important harms or unintended effects in each group | 45 | 44.12 | 0.96 | 0.91 to 1.01 | |
| Limitations | ||||||
| Discussion | 20 | Report of potential source of bias, imprecision, and multiple analyses | 47 | 46.08 | 0.9 | 0.82 to 0.98 |
| Generalizability | ||||||
| 21 | Generalizability (external validity, applicability) of the trial findings | 65 | 63.73 | 0.88 | 0.79 to 0.97 | |
| Interpretation | ||||||
| 22 | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence | 50 | 49.02 | 0.89 | 0.80 to 0.98 | |
| Registration | ||||||
| Other information | 23 | Registration number and name of trial registry | 12 | 11.76 | 1.00 | 1.00 |
| Protocol | ||||||
| 24 | Where the full-trial protocol can be accessed, if available | 36 | 35.29 | 1.00 | 1.00 | |
| Funding | ||||||
| 25 | Sources of funding and other support (such as supply of drugs) and role of funders | 47 | 46.08 | 1.00 | 1.00 | |
Assessment of reporting quality of needling details from STRICTA (n = 102 studies).
| Criteria | Item | Description | Number of positive trials | % | Cohen's | 95% CI |
|---|---|---|---|---|---|---|
| Acupuncture rationale | 1a | Style of acupuncture | 102 | 100 | 1.00 | 1.00 |
| 1b | Reasons for acupuncture treatment | 84 | 82.35 | 0.87 | 0.75 to 1.62 | |
| 1c | Explanation of changes was caused by what treatment | 27 | 26.47 | 1.00 | 1.00 | |
|
| ||||||
| Needling details | 2a | Number of needles insertions per session | 100 | 98.03 | 0.66 | 0.04 to 1.28 |
| 2b | Acupoint names (or location in case of nonchannel points) (unilateral or bilateral) | 62 | 60.78 | 0.90 | 0.82 to 0.98 | |
| 2c | Depth of insertion | 71 | 69.61 | 0.98 | 0.93 to 1.03 | |
| 2d | Responses sought (arrival of Qi) | 69 | 67.65 | 0.91 | 0.83 to 0.99 | |
| 2e | Needle stimulation (e.g., manual or electrical) | 94 | 92.16 | 0.83 | 0.64 to 1.02 | |
| 2f | Needle retention time | 99 | 97.06 | 1.00 | 1.00 | |
| 2g | Needle type (diameter, length, and manufacturer or material) | 65 | 63.73 | 0.92 | 0.85 to 0.99 | |
|
| ||||||
| Treatment regimen | 3a | Number of treatment sessions | 102 | 100 | 1.00 | 1.00 |
| 3b | Frequency and duration of treatment sessions | 102 | 100 | 1.00 | 1.00 | |
|
| ||||||
| Other components of treatment | 4a | Complementary interventions for the acupuncture group (e.g., moxibustion, cupping, exercises, and lifestyle advice) | 30 | 29.41 | 0.95 | 0.88 to 1.02 |
| 4b | Setting and context of treatment, including instructions to practitioners and information and explanations to patients | 11 | 10.78 | 0.79 | 0.61 to 0.97 | |
|
| ||||||
| Practitioner background | 5 | Description of practitioners | 18 | 17.65 | 0.94 | 0.86 to 1.02 |
| Control interventions | 6a | Rationale for the control or comparator in the context of the research question, with sources that justify the choice(s) | 33 | 32.35 | 0.87 | 0.77 to 0.97 |
| 6b | Precise description of the control or comparator intervention | 101 | 99.02 | 1.00 | 1.00 | |